Skip to main content
SpringerLink
Log in

I costi della broncopneumopatia cronica ostruttiva: la fase prospettica dello Studio ICE (Italian Costs for Exacerbations in COPD)

The costs of COPD

  • Published:
PharmacoEconomics Italian Research Articles

Summary

Introduction

Chronic obstructive pulmonary disease (COPD) is a cause of morbidity and mortality worldwide and imposes a huge individual and social burden. The present article reports the results from the prospective phase (results from the retrospective one were already published) of a multicentre Italian study (ICE, Italian Costs for Exacerbations in COPD). The aim of ICE was to assess the direct and indirect costs due to COPD, particularly regarding its exacerbations.

Materials and methods

The prospective phase was carried out on COPD patients admitted to 25 Hospital Centres (spread throughout over the country) because of an exacerbation occurring during the quarter October–December 2002. A 6-month follow-up following discharge was performed in each patient, via three telephone interviews every second month, based on a standard questionnaire and conducted by a clinical investigator. The sample was statistically stratified by three areas: Northern, Central, and Southern Italy.

Results

570 patients (mean age = 70.6 years; males = 69.2%) were eventually considered for processing. According to GOLD severity scale, patients were distributed as follows: 2a (moderate) → 36.4%; 2b (moderate-severe) → 31.3%; 3 (severe) → 32.3%. Respiratory failure affected 51.9% of the patients. Disease severity was found to be linked to smoking habits. 42% of exacerbations required hospitalisation. Medical costs for COPD totalled to € 4,645.5 per patient/year (€ 2,423.1 were related to exacerbations, € 2,222.4 to routine treatment); 40.1% of the total amount was for hospitalisations, 30.2% for oxygen therapy, 18% for drugs. Indirect costs (due to productivity losses by the patient and/or caregivers) were € 91.6 per patient/year. Costs resulted positively related to disease severity and to respiratory failure.

Conclusions

COPD is a disease with high costs, chiefly borne by the National Health Service: even a conservative estimate would find COPD responsible for 6% of the whole health care expenditure in Italy. The largest share of costs is for hospitalisations; hence, a strategy might be cost-effective that aimed at reducing exacerbations by improving diagnostic procedures and different treatment strategies, including drug therapy and pulmonary rehabilitation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Bibliografia

  1. Friedman M, Hilleman DE. Economic burden of chronic obstructive pulmonary disease: impact of new treatment options. Pharmacoecomomics 2001: 19(3): 245–54

    Article  CAS  Google Scholar 

  2. Murray CJ, Lopez AD. Alternative projection of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 1997; 349: 1498–504

    Article  PubMed  CAS  Google Scholar 

  3. http://www.goldcopd.com (sito consultato il 5/5/2004)

  4. Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19(6): 623–42

    Article  PubMed  CAS  Google Scholar 

  5. ISTAT. Indagine multiscopo sulle famiglie. Roma: Istituto Nazionale di Statistica, 1994

    Google Scholar 

  6. ISTAT. Annuario Statistico Italiano. Roma: Istituto Nazionale di Statistica, 2001

    Google Scholar 

  7. Hilleman DE, Dewan N, Malesker M, et al. Pharmacoeconomic evaluation of COPD. Chest 2000; 118(5): 1278–85

    Article  PubMed  CAS  Google Scholar 

  8. Strassels SA, Smith DH, Sullivan SD. The costs of treating COPD in the United States. Chest 2001; 119: 344–52

    Article  PubMed  CAS  Google Scholar 

  9. Lucioni C, Donner CF, De Benedetti F, et al. I costi della broncopneumopatia cronica ostruttiva in Italia: presentazione della prima fase dello studio ICE. Pharmacoeconomics-Italian Research Articles 2004; 6(1): 5–14

    Google Scholar 

  10. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256–76

    PubMed  CAS  Google Scholar 

  11. Lucioni C, Mazzi S, Neeser K. Analisi di costo-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia. Pharmacoeconomics-Italian Research Articles 2004; 6(2): 81–93

    Google Scholar 

  12. Ministero della Sanità. Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio Sanitario Nazionale e relative tariffe. Decreto Ministeriale 22 luglio 1996, Supplemento ordinario alla Gazzetta Ufficiale n. 216 del 14 settembre 1996

  13. Lucioni C, Garancini MP, Massi-Benedetti M, et al. per conto dell’Advisory Board Italiano dello Studio CODE-2. Il costo sociale del diabete di tipo 2 in Italia: lo studio CODE-2. Pharmacoeconomics-Italian Research Articles 2000; 2(1): 1–21

    Google Scholar 

  14. ISTAT. Annuario Statistico Italiano. Roma: Istituto Nazionale di Statistica, 2003

    Google Scholar 

  15. L’Informatore Farmaceutico 2003. Milano: OEMF, 2003

  16. Garattini L, Cornago D. Ossigenoterapia a lungo termine: modalità di acquisto e distribuzione in Italia. Economia & Politica del Farmaco 2004; 1(2): 29–36

    Google Scholar 

  17. Valori medi rilevati presso alcuni centri partecipanti allo studio ICE. Dato non pubblicato, disponibile on file.

  18. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60: 429–62

    Article  PubMed  CAS  Google Scholar 

  19. Koopmanschap MA, Rutten FFH. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics 1993; 4(6): 446–54

    Article  PubMed  CAS  Google Scholar 

  20. Koopmanschap MA, Rutten FFH. The impact of indirect costs on outcomes of health care programs. Health Econ 1994; 3: 385–93

    Article  PubMed  CAS  Google Scholar 

  21. Koopmanschap MA, Rutten FFH, van Ineveld MA, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–89

    Article  PubMed  CAS  Google Scholar 

  22. Zuccaro P, Pichini S, Mortali C, et al. Fumo e patologie respiratorie: le carte del rischio per broncopneumopatia cronica ostruttiva e tumore al polmone. Roma: Istituto Superiore di Sanità, 2004

    Google Scholar 

  23. Mantovani LG, Mannino S, Donner CF, et al. The cost of COPD: results from the SIRIBO (Studio Italiano sulle Riacutizzazioni Infettive delle Bronchiti). Eur Respir J 2002; 20 (Suppl. 38): 125 (plus poster)

    Google Scholar 

  24. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003; 123(3): 784–91

    Article  PubMed  Google Scholar 

  25. Jansson S-A, Andersson F, Borg S, et al. Costs of COPD in Sweden according to Disease Study. Chest 2002; 122(6): 1994–2002

    Article  PubMed  Google Scholar 

  26. Decramer M, Gosselink R, Troosters T. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997; 10: 417–23

    Article  PubMed  CAS  Google Scholar 

  27. Detournay B, Pribil C, Fournier M, et al.; the SCOPE group. The SCOPE Study: health care consumption related to patients with chronic obstructive pulmonary disease in France. Value Health 2004; 7(2): 168–74

    Article  PubMed  CAS  Google Scholar 

  28. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000; 118(5): 1278–85

    Article  PubMed  CAS  Google Scholar 

  29. ASSR, Agenzia per i Servizi Sanitari Regionali. Evoluzione della spesa sanitaria dal 1995 al 2001. Monitor 2003; 3: 62–7

    Google Scholar 

  30. ASSR, Agenzia per i Servizi Sanitari Regionali. La spesa sanitaria e altri indicatori di salute nei dati OCSE 2003. Monitor 2003; 6: 67–72

    Google Scholar 

  31. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003; 97 (Suppl. C): S43–50

    Article  Google Scholar 

  32. SPLF. Health management of chronic obstructive pulmonary disease: summary of the recommendations of the French pneumological society (SPLF). Presse Médicale 1997; 36: 225–32

    Google Scholar 

  33. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 (5 pt 2): S77–S121

    Google Scholar 

  34. Anthonisen NR, Connett JE, Kiley JP. Effects of smoking intervention and the use of an inhaled anti-cholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study. JAMA 1994; 272: 1497–505

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health, Adis International Ltd. Italy, Via Lanino 5, 20144, Milano, Italia

    C. Lucioni & S. Mazzi

  2. Divisione di Pneumologia, IRCCS Fondazione S. Maugeri, Veruno (NO), Italia

    C. F. Donner

  3. UOC di Pneumologia, POS Camillo De Lellis, Chieti, Italia

    F. De Benedetto

  4. Riabilitazione Cardio-Pneumologica, AUSL Reggio Emilia, Ospedale S. Sebastiano, Correggio, RE, Italia

    M. Lusuardi

  5. Dipartimento Cardiotoracico e UO di Pneumologia e Fisiopatologia Respiratoria, Università di Pisa, Italia

    P. L. Paggiaro

  6. UOC di Pneumologia, ACO San Filippo Neri, Roma, Italia

    C. M. Sanguinetti

Authors
  1. C. Lucioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. F. Donner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. De Benedetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Lusuardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Mazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. L. Paggiaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. M. Sanguinetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Lucioni.

Additional information

I peer reviewers, per questo articolo, sono stati coordinati da Mario Eandi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lucioni, C., Donner, C.F., De Benedetto, F. et al. I costi della broncopneumopatia cronica ostruttiva: la fase prospettica dello Studio ICE (Italian Costs for Exacerbations in COPD). Pharmacoeconomics-Ital-Res-Articles 7, 119–134 (2005). https://doi.org/10.1007/BF03320542

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03320542

Search

Navigation